Anne Grete Semb

Anne Grete Semb

Auto-generated profile, based on publicly available information

Anne Grete Semb

Diakonhjemmet Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
CVChristiaan Vrints
Christiaan Vrints
FAFelicita Andreotti
Felicita Andreotti
KKKonstantinos C Koskinas
Konstantinos C Koskinas
XRXavier Rossello
Xavier Rossello
MAMarianna Adamo
Marianna Adamo
ASAleksandr Borisovich Shek
Aleksandr Borisovich Shek

29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
JSJeanette Schulz-Menger
Jeanette Schulz-Menger
VCValentino Collini
Valentino Collini
JGJan Wolfgang Gröschel
Jan Wolfgang Gröschel
YAYehuda Adler
Yehuda Adler
ABAntonio Brucato
Antonio Brucato
AKAmayak Kevorkov
Amayak Kevorkov

3 June 2020 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
ASAnne Grete Semb
Anne Grete Semb
EIEirik Ikdahl
Eirik Ikdahl
GWGrunde Wibetoe
Grunde Wibetoe
CCCynthia Crowson
Cynthia Crowson
SRSilvia Rollefstad
Silvia Rollefstad

1 November 2010 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
ASA G Semb
A G Semb
TKT K Kvien
T K Kvien
AAA H Aastveit
A H Aastveit
IJI Jungner
I Jungner
TPT R Pedersen
T R Pedersen
IHI Holme
I Holme
Objectives To examine the rates of acute myocardial infarction (AMI) and ischaemic stroke (IS) and to examine the predictive value of total cholesterol (TC) and triglycerides (TG) for AMI and IS in patients with rheumatoid arthritis (RA) and people without RA. Methods In the Apolipoprotein MOrtality RISk (AMORIS) Study 480 406 people (including 1779 with RA, of whom 214 had an AMI and 165 an IS) were followed for 11.8 (range 7–17) years. Cox regression analysis was used to calculate HR per SD increase in TC or TG with 95% CI. All values were adjusted for age, diabetes and hypertension. Results The levels of TC and TG were significantly lower in patients with RA than in people without RA. Despite this, the rate of AMI and IS per 1000 years was at least 1.6 times higher in RA than non-RA. TC was nearly significantly predictive for AMI (HR/SD 1.13 (95% CI 0.99 to 1.29), p=0.07) and significantly predictive for future IS in RA (HR/SD 1.20 (95% CI 1.03 to 1.40), p=0.02). TG had no relationship to development of AMI (1.07, 0.94 to 1.21, p=0.29), but was weakly related to IS (1.13, 0.99 to 1.27, p=0.06). In contrast, both TC and TG were significant predictors of AMI and IS in people without RA. Conclusions Patients with RA had 1.6 times higher rate of AMI and IS than people without RA. TC and TG were significant predictors of AMI and IS in people without RA, whereas the predictive value in RA was not consistent.

4 April 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
AKAnne Kerola
Anne Kerola
AKAmirhossein Kazemi
Amirhossein Kazemi
SRSilvia Rollefstad
Silvia Rollefstad
SLSiri Lillegraven
Siri Lillegraven
JSJoseph Sexton
Joseph Sexton
ASAnne Grete Semb
Anne Grete Semb
Objectives: To explore mortality and causes of death among Norwegian patients with RA, PsA and axial spondyloarthritis (axSpA) compared with the general population by conducting a nationwide registry-based cohort study. Methods: Patients with RA, PsA and axSpA were identified from the Norwegian Patient Registry based on ICD-10 codes between 2008 and 2017. Using age as the time variable, all-cause and cause-specific mortality were estimated between 2010 and 2017 with the Kaplan–Meier estimator and the cumulative incidence competing risk method, respectively. Sex-, education level-, health region- and age group-adjusted hazard ratios (HRs) for mortality were estimated using Cox regression models. Results: We identified 36 095 RA, 18 700 PsA and 16 524 axSpA patients (70%, 53% and 45% women, respectively). RA and axSpA were associated with increased all-cause mortality (HR 1.45 [95% CI: 1.41, 1.48] and HR 1.38 [95% CI: 1.28, 1.38], respectively). Women but not men with PsA had a slightly increased mortality rate (HR 1.10 [95% CI: 1.00, 1.21] among women and 1.02 [95% CI: 0.93, 1.11] among men). For all patient groups as well as for the general population, the three leading causes of death were cardiovascular diseases, neoplasms and respiratory diseases. RA patients had increased mortality from all of these causes, while axSpA patients had increased mortality from cardiovascular and respiratory diseases. Conclusion: Even in the era of modern treatments for IJDs, patients with RA and axSpA still have shortened life expectancy. Our findings warrant further attention to the prevention and management of comorbidities.

15 January 2013 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
ASAnne G. Semb
Anne G. Semb
SRSilvia Rollefstad
Silvia Rollefstad
SPSella Aarrestad Provan
Sella Aarrestad Provan
TKTore K. Kvien
Tore K. Kvien
ESEinar Stranden
Einar Stranden
JHJonny Hisdal
Jonny Hisdal
Objective. Carotid plaques (CP) are predictive of acute coronary syndrome in patients with rheumatoid arthritis (RA), suggesting that atherosclerotic plaques in these patients are vulnerable. The objective of our study was to characterize vulnerability of CP in patients with RA compared to a control population, and between RA patients with different levels of disease activity. Methods. Ultrasound examination of carotid arteries was performed in 152 patients with RA and 89 controls. CP echolucency was evaluated by the Gray-Scale Median (GSM) technique. Lower GSM values indicate higher vulnerability of plaques. CP characteristics were compared between RA patients with active disease and in remission, and between patients and controls. All analyses were performed with adjustment for confounding factors (sex, age, smoking, and blood pressure). Poisson regression analysis was used for count data, mixed modeling for GSM and area per plaque, and analysis of covariance for minimum GSM value per patient. Results. Patients with RA more frequently had CP (median 2, range 0, 4) compared with controls (median 1, range 0, 3; p < 0.001), after adjustment for age and sex. Patients with active RA disease according to the Clinical Disease Activity Index (CDAI) had lower median GSM (p = 0.03), minimum GSM (p = 0.03), and a larger CP area (although the latter finding was not significant; p = 0.27), compared with patients with RA in remission. These findings were not confirmed for other disease measures (Simplified Disease Activity Index, Disease Activity Score-28, C-reactive protein, erythrocyte sedimentation rate). Conclusion. Patients with RA had more CP compared with controls and patients in CDAI remission, and controls had more stable CP than patients with active disease; these findings point to the importance of achieving remission in RA.